Leeward Investments LLC MA Has $15.32 Million Stock Holdings in Envista Holdings Co. (NYSE:NVST)

Leeward Investments LLC MA decreased its holdings in Envista Holdings Co. (NYSE:NVST) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 636,627 shares of the company’s stock after selling 10,948 shares during the quarter. Leeward Investments LLC MA owned 0.37% of Envista worth $15,317,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Foundry Partners LLC bought a new stake in shares of Envista in the 4th quarter worth about $3,571,000. Raymond James & Associates grew its holdings in shares of Envista by 820.6% in the 4th quarter. Raymond James & Associates now owns 408,218 shares of the company’s stock worth $9,822,000 after purchasing an additional 363,875 shares during the last quarter. River Road Asset Management LLC bought a new stake in Envista during the 4th quarter worth about $54,931,000. DAVENPORT & Co LLC bought a new stake in Envista during the 4th quarter worth about $13,233,000. Finally, Blueshift Asset Management LLC grew its holdings in Envista by 168.7% during the 3rd quarter. Blueshift Asset Management LLC now owns 41,524 shares of the company’s stock worth $1,158,000 after acquiring an additional 26,073 shares during the last quarter.

Envista Price Performance

Shares of NVST stock opened at $20.39 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.90 and a current ratio of 2.23. The company’s 50 day moving average price is $20.95 and its two-hundred day moving average price is $22.72. Envista Holdings Co. has a 52 week low of $18.95 and a 52 week high of $38.68.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The business had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. During the same quarter last year, the business earned $0.52 earnings per share. Envista’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities research analysts forecast that Envista Holdings Co. will post 1.43 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVST shares. TheStreet lowered shares of Envista from a “c” rating to a “d+” rating in a report on Wednesday, February 7th. Leerink Partnrs reaffirmed an “underperform” rating on shares of Envista in a research note on Monday, February 26th. Jefferies Financial Group lowered shares of Envista from a “buy” rating to a “hold” rating and reduced their target price for the company from $30.00 to $23.00 in a research note on Friday, February 9th. William Blair downgraded shares of Envista from an “outperform” rating to a “market perform” rating in a research report on Thursday, February 8th. Finally, UBS Group started coverage on shares of Envista in a research report on Friday, January 5th. They issued a “neutral” rating and a $26.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $27.90.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.